|
1
|
Duggan ST and Keating GM: Pegylated
liposomal doxorubicin: A review of its use in metastatic breast
cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's
sarcoma. Drugs. 71:2531–2558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cortés-Funes H and Coronado C: Role of
anthracyclines in the era of targeted therapy. Cardiovasc Toxicol.
7:56–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: Molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang YY, Yi M and Huang YP: Oxymatrine
ameliorates doxorubicin-induced cardiotoxicity in rats. Cell
Physiol Biochem. 43:626–635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bordoni A, Biagi P and Hrelia S: The
impairment of essential fatty acid metabolism as a key factor in
doxorubicin-induced damage in cultured rat cardiomyocytes. Biochim
Biophys Acta. 1440:100–106. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chatterjee K, Zhang J, Honbo N and
Karliner JS: Doxorubicin cardiomyopathy. Cardiology. 115:155–162.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Christiansen S: Clinical management of
doxorubicin-induced heart failure. J Cardiovasc Surg (Torino).
52:133–138. 2011.PubMed/NCBI
|
|
8
|
Ludke AR, Al-Shudiefat AA, Dhingra S,
Jassal DS and Singal PK: A concise description of cardioprotective
strategies in doxorubicin-induced cardiotoxicity. Can J Physiol
Pharmacol. 87:756–763. 2009.PubMed/NCBI
|
|
9
|
Tan HL, Chan KG, Pusparajah P, Duangjai A,
Saokaew S, Mehmood Khan T, Lee LH and Goh BH: Rhizoma coptidis: A
potential cardiovascular protective agent. Front Pharmacol.
7:362.eCollection 20162016. View Article : Google Scholar
|
|
10
|
Tabeshpour J, Imenshahidi M and
Hosseinzadeh H: A review of the effects of Berberis vulgaris and
its major component, berberine, in metabolic syndrome. Iran J Basic
Med Sci. 20:557–568. 2017.PubMed/NCBI
|
|
11
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals = Guide for the Care and Use of Laboratory Animals. 8th.
Washington (DC): National Academies Press (US); 2011
|
|
12
|
Chen X, Zhang Y, Zhu Z, Liu H, Guo H,
Xiong C, Xie K, Zhang X and Su S: Protective effect of berberine on
doxorubicin induced acute hepatorenal toxicity in rats. Mol Med
Rep. 13:3953–3960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kelishomi RB, Ejtemaeemehr S, Tavangar SM,
Rahimian R, Mobarakeh JI and Dehpour AR: Morphine is protective
against doxorubicin-induced cardiotoxicity in rat. Toxicology.
243:96–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiong C, Li JX, Guo HC, Zhang LN, Guo W,
Meng J and Wang YL: The H1-H2 domain of the
α1 isoform of Na+-K+-ATPase is involved in ouabain toxicity in rat
ventricular myocytes. Toxicol Appl Pharmacol. 262:32–42. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Asensio-López MC, Soler F, Pascual-Figal
D, Fernández-Belda F and Lax A: Doxorubicin-induced oxidative
stress: The protective effect of nicorandil on HL-1 cardiomyocytes.
PLoS One. 12:e01728032017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jain D, Ahmad T, Cairo M and Aronow W:
Cardiotoxicity of cancer chemotherapy: Identification, prevention
and treatment. Ann Transl Med. 5:3482017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li T, Danelisen I and Singal PK: Early
changes in myocardial antioxidant enzymes in rats treated with
adriamycin. Mol Cell Biochem. 232:19–26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee IA, Hyun YJ and Kim DH: Berberine
ameliorates TNBS-induced colitis by inhibiting lipid peroxidation,
enterobacterial growth and NF-κB activation. Eur J Pharmacol.
648:162–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li P, Ren J, Duan C, Lin C and Liu J:
Effects of four components of Rhizoma Corydalis on anoxia and
peroxidation injuries in neonatal cardiomyocytes. Zhongguo Zhong
Yao Za Zhi. 35:84–88. 2010.(In Chinese). PubMed/NCBI
|
|
20
|
Che FF, Liu Y and Xu CG: Schisandrin B
prevents doxorubicin-induced cardiotoxicity in rabbits. Sichuan Da
Xue Xue Bao Yi Xue Ban. 41:24–28. 2010.(In Chinese). PubMed/NCBI
|
|
21
|
Li T and Singal PK: Adriamycin-induced
early changes in myocardial antioxidant enzymes and their
modulation by probucol. Circulation. 102:2105–2110. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tong N, Zhang J, Chen Y, Li Z, Luo Y, Zuo
H and Zhao X: Berberine sensitizes mutliple human cancer cells to
the anticancer effects of doxorubicin in vitro. Oncol Lett.
3:1263–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patil JB, Kim J and Jayaprakasha GK:
Berberine induces apoptosis in breast cancer cells (MCF-7) through
mitochondrial-dependent pathway. Eur J Pharmacol. 645:70–78. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang YJ, Yang SH, Li MH, Iqbal J,
Bourantas CV, Mi QY, Yu YH, Li JJ, Zhao SL, Tian NL and Chen SL:
Berberine attenuates adverse left ventricular remodeling and
cardiac dysfunction after acute myocardial infarction in rats: Role
of autophagy. Clin Exp Pharmacol Physiol. 41:995–1002. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takemura G and Fujiwara H:
Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms
to management. Prog Cardiovasc Dis. 49:330–352. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hao G, Yu Y, Gu B, Xing Y and Xue M:
Protective effects of berberine against doxorubicin-induced
cardiotoxicity in rats by inhibiting metabolism of doxorubicin.
Xenobiotica. 45:1024–1029. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang S, Konorev EA, Kotamraju S, Joseph J,
Kalivendi S and Kalyanaraman B: Doxorubicin induces apoptosis in
normal and tumor cells via distinctly different mechanisms.
Intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem.
279:25535–25543. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Solem LE, Henry TR and Wallace KB:
Disruption of mitochondrial calcium homeostasis following chronic
doxorubicin administration. Toxicol Appl Pharmacol. 129:214–222.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zorzato F, Sarviati G, Facchinetti T and
Volpe P: Doxorubicin induces calcium release from terminal
cisternae of skeletal muscle. A study on isolated sarcoplasmic
reticulum and chemically skinned fibers. J Biol Chem.
260:7349–7355. 1985.PubMed/NCBI
|
|
30
|
Kim DH, Landry AB III, Lee YS and Katz AM:
Doxorubicin-induced calcium release from sarcoplasmic reticulum
vesicles. J Moll Cell Cardiol. 21:433–436. 1989. View Article : Google Scholar
|
|
31
|
Caroni P, Villani F and Carafoli E: The
cardiotoxic antibiotic doxorubicin inhibits the Na+/Ca2+ exchange
of dog heart sarcolemmal vesicles. FEBS Lett. 130:184–186. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Keung EC, Toll L, Ellis M and Jensen RA:
L-type cardiac calcium channels in doxorubicin cardiomyopathy in
rats morphological, biochemical, and functional correlations. J
Clin Invest. 87:2108–2113. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Przygodzki T, Sokal A and Bryszewska M:
Calcium ionophore A23187 action on cardiac myocytes is accompanied
by enhanced production of reactive oxygen species. Biochim Biophys
Acta. 1740:481–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Petrosillo G, Ruggiero FM, Pistolese M and
Paradies G: Ca2+-induced reactive oxygen species production
promotes cytochrome c release from rat liver mitochondria via
mitochondrial permeability transition (MPT)-dependent and
MPT-independent mechanisms: Role of cardiolipin. J Biol Chem.
279:53103–53108. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Waring P: Redox active calcium ion
channels and cell death. Arch Biochem Biophys. 434:33–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li L, Takemura G, Li Y, Miyata S, Esaki M,
Okada H, Kanamori H, Khai NC, Maruyama R, Ogino A, et al:
Preventive effect of erythropoietin on cardiac dysfunction in
Doxorubicin-induced cardiomyopathy. Circulation. 113:535–543. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yeh YC, Lai HC, Ting CT, Lee WL, Wang LC,
Wang KY, Lai HC and Liu TJ: Protection by doxycycline against
doxorubicin-induced oxidative stress and apoptosis in mouse testes.
Biochem Pharmacol. 74:969–980. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rahn CA, Bombick DW and Doolittle DJ:
Assessment of mitochondrial membrane potential as an indicator of
cytotoxicity. Fundam Appl Toxicol. 16:435–448. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lv X, Yu X, Wang Y, Wang F, Li H, Wang Y,
Lu D, Qi R and Wang H: Berberine inhibits doxorubicin-triggered
cardiomyocyte apoptosis via attenuating mitochondrial dysfunction
and increasing Bcl-2 expression. PLoS One. 7:e473512012. View Article : Google Scholar : PubMed/NCBI
|
